CONMED Corporation reported second quarter 2026 financial results on July 29, 2026. Sales were $343.5 million, a 0.3% increase year-over-year, with organic constant currency sales rising 6.0%. Diluted earnings per share reached $0.77 (GAAP) and $1.38 (adjusted), both up significantly from the prior year period. The company updated its full-year 2026 guidance, raising net sales estimates to a range of $1,358 million to $1,373 million and adjusted diluted EPS to $4.48–$4.60. Operational highlights included the completion of strategic exits from gastroenterology product offerings and refinancing a portion of debt. CONMED Corporation operates in the medical device industry, manufacturing surgical equipment and instruments.

On June 17, 2026, CONMED Corporation announced the appointment of John E. Gallagher as Executive Vice President, Chief Financial Officer, principal financial officer, and principal accounting officer, effective July 15, 2026. Mr. Gallagher joins from Certara, Inc. and will receive an annual base salary of $650,000, a target annual cash bonus of 85% of base salary, and a one-time cash bonus of $34,750 if employed through December 31, 2026. His equity package includes $575,000 in options, $1,150,000 in restricted stock units (RSUs), $575,000 in performance stock units, and a $1,500,000 make-whole RSU grant. Upon the effective date, Patrick Beyer will cease serving as Interim Principal Financial Officer and Kimberly Lockwood will cease serving as Interim Principal Accounting Officer. CONMED Corporation is a medical technology company that develops and manufactures surgical and medical products.